Hepatitis Testing (HBV, HCV, HAV, HDV) Laboratory Criteria
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Illinois Policy CPCPLABO1S alerts
Get alerted when Policy CPCPLABO1S changes without checking for updates manually.
Monitor payer policy activity
Lab management and reimbursement criteria for hepatitis A, B, C, and D testing for Blue Cross Blue Shield of Illinois members; defines which tests and indications may be reimbursable and references required coding and documentation expectations. Affects laboratories, ordering providers, and claims processing for BCBSIL-covered members.
New policy effective 01/01/2026.
Coverage Criteria — Hepatitis Testing
Hepatitis B — Covered with criteria
HBV testing coverage statements
Hepatitis C — Covered with criteria
HCV testing coverage statements
Hepatitis A and D — Covered with criteria / Exclusions
HAV and HDV testing coverage statements
Quantitative nucleic acid testing for hepatitis A virus (HAV) and hepatitis D virus (HDV) viral loads is not reimbursable. The policy specifies that while qualitative HAV or HDV testing and serologic evaluation may be reimbursable as clinically indicated, quantitative HAV RNA and quantitative HDV RNA assays are excluded from reimbursement.
Do not repeat hepatitis C virus (HCV) antibody testing in individuals with a previously positive HCV antibody result. Per referenced guidance, when prior HCV antibody is positive, providers should order HCV viral load (HCV RNA) testing to assess for active versus resolved infection rather than repeating antibody testing.
Covered Indications and Clinical Use
Assessment of active versus resolved HCV infection — order HCV viral load rather than repeat antibody if prior positive.
Assessment of active versus resolved HCV infection
Frequency Limits and Screening Intervals
Procedure Codes and Coding Notes
Provider Actions, Billing & Documentation
Procedure codes and product applicability
Verify coverage and prior authorization per product — not all requirements apply to each product. The inclusion of a procedure code does not guarantee coverage or reimbursement. Providers should review member plan documents for eligibility and benefit details.
- Not all requirements apply to each product
- Inclusion of a code does not guarantee coverage or reimbursement
Claims documentation and coding requirements
Providers are responsible for submission of accurate documentation of services performed and must code claims using valid HIPAA-approved code sets. Claims should be coded according to industry-standard coding guidelines (e.g., AMA CPT, HCPCS, ICD-10-CM/PCS, CMS NCCI) and may be reviewed for compliance with benefit terms, provider contract language, clinical payment and coding policies, and coding software logic. Upon request, providers must submit any additional documentation to support the claim.
- Submit claims with valid HIPAA-approved codes
- Follow AMA CPT, HCPCS, ICD-10, NCCI and other industry coding guidelines
- Be prepared to provide additional documentation upon request
Coding and documentation risk
Claims not coded appropriately or lacking required documentation may be subject to review and denial. Providers should ensure accurate coding and complete supporting records to avoid claim denials or recoupment.
- Claims may be reviewed and denied if coding or documentation is incomplete or incorrect
- Providers may be asked to provide records to substantiate medical necessity and coding
Denial triggers
No explicit denial triggers are stated in this policy section beyond the general risk that claims lacking proper coding or documentation may be reviewed or denied. Providers should follow the documentation and coding requirements above and verify product-specific rules and prior authorization requirements separately.
- No specific, standalone denial triggers listed in this section
- Follow documentation/coding rules and check product-specific prior authorization
Clinical guideline references
This policy references multiple clinical guidelines that inform appropriate test use and interpretation, including guidance from AASLD, WHO, EASL, and AGA. Providers should follow these specialty society recommendations when ordering tests and interpreting results.
- AASLD, WHO, EASL, AGA and other listed clinical guideline sources
- References include multiple society guidance documents through 2025
Ordering Requirements and Restrictions
Review plan documents for coverage and coding
Providers should review member plan documents to determine eligible coverage for hepatitis testing and ensure appropriate coding prior to ordering services.
- Confirm member-specific benefits, coverage limitations, and any product-specific prior authorization requirements in the member's plan documents.
- Verify that codes selected for billing match the tests ordered and are supported by the clinical indication.
No explicit ordering provider restrictions; follow clinical guidance
The policy does not impose explicit restrictions on who may order the tests; ordering should be guided by the clinical criteria and referenced guideline sources.
- Use guideline recommendations (AASLD, WHO, EASL, AGA) to determine appropriate ordering based on clinical indications.
- No provider-type ordering limitations are specified in the policy text provided.
Not Covered Services and Exclusions
The following tests are considered not covered: quantitative nucleic acid testing for HAV viral load and quantitative nucleic acid testing for HDV viral load. Qualitative testing or serologic assays for HAV and HDV may be reimbursable when clinically indicated, but quantitative viral-load assays for these viruses are excluded from reimbursement.
Repeating HCV antibody testing in a patient with a prior positive HCV antibody is discouraged. Clinical guidance cited in this policy directs clinicians to pursue HCV RNA (viral load) testing to distinguish active infection from a resolved infection instead of performing another antibody test.
Background and Rationale
Hepatitis viruses A, B, C, and D have distinct epidemiologies, transmission routes, and clinical implications; testing strategies differ by virus and clinical context. Serologic assays (antibody and antigen tests), qualitative nucleic acid tests, and quantitative viral-load tests serve different roles: for example, antibody screening identifies prior exposure, qualitative nucleic acid testing can confirm acute or perinatal infection, and quantitative HCV RNA is used for treatment monitoring. Policy guidance within this document aligns testing recommendations with clinical indications and external guidance sources (AASLD, WHO and related guidance) to clarify when screening, confirmatory, and monitoring tests are reimbursable.
Definitions and Test Descriptions
Policy Update History
Policy created with effective date 2026-01-01 (new policy).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.